Hudson Value Partners LLC Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Hudson Value Partners LLC lifted its stake in Amgen Inc. (NASDAQ:AMGNFree Report) by 176.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,330 shares of the medical research company’s stock after buying an additional 8,510 shares during the period. Amgen makes up approximately 1.8% of Hudson Value Partners LLC’s holdings, making the stock its 18th largest holding. Hudson Value Partners LLC’s holdings in Amgen were worth $3,839,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Glassman Wealth Services grew its stake in shares of Amgen by 12.4% in the fourth quarter. Glassman Wealth Services now owns 864 shares of the medical research company’s stock worth $249,000 after purchasing an additional 95 shares during the last quarter. Godshalk Welsh Capital Management Inc. bought a new stake in shares of Amgen in the fourth quarter worth about $206,000. Nomura Asset Management Co. Ltd. grew its stake in shares of Amgen by 1.4% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 381,262 shares of the medical research company’s stock worth $109,811,000 after purchasing an additional 5,125 shares during the last quarter. Nixon Peabody Trust Co. bought a new stake in shares of Amgen in the fourth quarter worth about $447,000. Finally, Skopos Labs Inc. bought a new stake in shares of Amgen in the fourth quarter worth about $990,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AMGN. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. BMO Capital Markets lifted their price objective on Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Mizuho lifted their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. The Goldman Sachs Group lifted their price objective on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada cut their price objective on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $305.65.

View Our Latest Research Report on AMGN

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $0.66 during midday trading on Friday, hitting $305.84. The company had a trading volume of 2,425,864 shares, compared to its average volume of 2,869,476. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The company has a market cap of $164.06 billion, a price-to-earnings ratio of 43.69, a PEG ratio of 2.76 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a fifty day moving average of $285.02 and a two-hundred day moving average of $285.61.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. Amgen’s revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.98 EPS. On average, equities research analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.94%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is currently 128.57%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.